Table 2

Differences between those patients with and without active arthralgias

Active arthralgiasInactive arthralgiasP value
Age(mean in years (SD))65 (44)40 (16)0.96
Female gender (n (%))41 (26)24 (22)0.38
Body mass index (mean in kg (SD))83.7 (23)79 (20)0.09
Crohn’s disease (vs ulcerative colitis) (n (%))47 (72)143 (71)0.82
Disease duration (mean in years (SD))13 (11)11 (9)0.91
Trough level of infliximab (median (IQR))8.7 (2.1–31.8)8.7 (3.5–16.7)0.48
Detectable anti-infliximab antibody (n (%))13 (20)23 (11)0.08
Time on infliximab (median in months (IQR))13 (8–27)14 (8–36)0.54
Combination therapy with an immunomodulator* (n (%))35 (54)109 (54)0.81
On methotrexate (vs a thiopurine)* (n (%))8 (25)26 (25.2)0.98
Active inflammatory bowel disease (n (%))33 (51)86 (43)0.25
SIBDQ (median (IQR))47 (38–57)54 (41–61)0.031†
Harvey Bradshaw Index‡ (median (IQR))3 (1–6)1 (0–3)0.0003†
Partial Mayo score§ (median (IQR))2 (0–4)1 (0–3)0.9
Ocular extra-intestinal manifestations (n (%))7 (11)6 (3)0.011†
Primary sclerosis cholangitis (n (%))1 (1.5)6 (3)0.53
  • *Only patients on combination therapy.

  • †Statistically significant.

  • ‡Only patients with Crohn’s disease.

  • §Only patients with ulcerative colitis.

  • SIBDQ, Short Inflammatory Bowel Diseases Questionnaire.